HomeFileStructural heart disease

Structural heart disease

View Category

Other

AHA 2018 | Endocarditis Prophylaxis More Limited after AHA 2007 Guidelines

The incidence of infective endocarditis had decreased after AHA 2007 recommendations. At present, some patients are not...
solaci -
Learn More
Structural heart disease

CoreValve US Pivotal High Risk Trial: at 5 years, similar results

Courtesy of Dr. Carlos Fava. We are well aware of transcatheter aortic valve replacement’s (TAVR) effect in high-risk...
solaci -
Learn More
Structural heart disease

Surprises in the Physiopathology of Critical Ischemia

Luminal thrombotic occlusions associated with non-significant atherosclerosis are commonly observed in patients with critical lower limb ischemia,...
solaci -
Learn More
Structural heart disease

Differences in Stroke between TAVR and SAVR in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVR) is more and more frequent in lower risk populations that had previously...
solaci -
Learn More
Structural heart disease

TAVR in Low-Risk Patients with “Zero” Mortality and “Zero” Stroke

Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients with symptomatic severe aortic...
solaci -
Learn More
Structural heart disease

How to predict post TAVR quality of life in “real world” patients

Despite the benefit for most patients, a small number of patients still show poor outcomes after transcatheter...
solaci -
Learn More
Chronic Ischemic cardiopathy

What Should We Use for the Functional Assessment of Coronary Lesions in Severe Aortic Stenosis?

This systematic analysis measured intracoronary pressure in different phases of the cardiac cycle and flow velocity in...
solaci -
Learn More
Antithrombotic Anticoagulants

Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates

Patients undergoing transcatheter aortic valve replacement (TAVR) randomized to rivaroxaban in the GALILEO trial experienced higher risk...
solaci -
Learn More